Evidence and Recommendations for Imaging Liver Fat in Children, Based on Systematic Review  by Awai, Hannah I. et al.
Clinical Gastroenterology and Hepatology 2014;12:765–773Evidence and Recommendations for Imaging Liver Fat in Children,
Based on Systematic Review
Hannah I. Awai,*,‡,§ Kimberly P. Newton,*,‡ Claude B. Sirlin,§ Cynthia Behling,k and
Jeffrey B. Schwimmer*,‡,§
*Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, §Liver Imaging Group, Department of
Radiology, University of California, San Diego School of Medicine, San Diego; ‡Department of Gastroenterology, Rady
Children’s Hospital San Diego, San Diego; and kDepartment of Pathology, Sharp Medical Center,
San Diego, CaliforniaBACKGROUND & AIMS: Fatty liver is a common problem in children and increases their risk for cirrhosis, diabetes, and
cardiovascular disease. Liver biopsy is the clinical standard for diagnosing and grading fatty
liver. However, noninvasive imaging modalities are needed to assess liver fat in children. We
performed a systematic review of studies that evaluated imaging liver fat in children.METHODS: We searched PubMed for original research articles in peer-reviewed journals from January 1,
1982, through December 31, 2012, using the key words “imaging liver fat.” Studies included
those in English, and those performed in children from birth to 18 years of age. To be eligible
for inclusion, studies were required to measure hepatic steatosis via an imaging modality and a
quantitative comparator as the reference standard.RESULTS: We analyzed 9 studies comprising 610 children; 4 studies assessed ultrasonography and
5 studies assessed magnetic resonance imaging (MRI). Ultrasonography was used in the diag-
nosis of fatty liver with positive predictive values of 47% to 62%. There was not a consistent
relationship between ultrasound steatosis score and the reference measurement of hepatic
steatosis. Liver fat as measurements by MRI or by spectroscopy varied with the methodologies
used. Liver fat measurements by MRI correlated with results from histologic analyses, but
sample size did not allow for an assessment of diagnostic accuracy.CONCLUSIONS: Available evidence does not support the use of ultrasonography for the diagnosis or grading of
fatty liver in children. Although MRI is a promising approach, the data are insufﬁcient to make
evidence-based recommendations regarding its use in children for the assessment of hepatic
steatosis.Keywords: NAFLD; Evidence-Based Medicine; Liver Imaging.Watch this article’s video abstract and others at
http://tiny.cc/bz9jv.Scan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.atty liver is common in children with an estimated
Abbreviations used in this paper: CT, computed tomography; GRADE,
Grading of Recommendation Assessment, Development, and Evaluation;
IP, in phase; MRI, magnetic resonance imaging; MRS, magnetic reso-
nance spectroscopy; OP, out-of-phase; NAFLD, nonalcoholic fatty liver
disease.
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Open access under CC BY-NC-ND license.Fprevalence of 9.6%,1 and is characterized histo-
logically by hepatic steatosis, the accumulation of tri-
glycerides within the cytoplasm of hepatocytes. Because
of the high prevalence of obesity, there are many chil-
dren at risk for fatty liver in the form of nonalcoholic
fatty liver disease (NAFLD). NAFLD, which encompassesa broad spectrum of liver disease severity, including
steatosis, steatohepatitis with or without ﬁbrosis, and
cirrhosis, is only one of many conditions in which hepatic
steatosis is an important histologic component. Hepatic
steatosis also can occur in drug toxicity, metabolic dis-
ease, viral hepatitis, cystic ﬁbrosis, protein malnutrition,
and Wilson disease. Furthermore, fatty liver is regarded
as a cardiometabolic risk factor that can contribute to
Figure 1. Application of the inclusion and exclusion criteria
used for the structured review.
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The multitude of clinical conditions associated with he-
patic steatosis as well as their prevalence and severity
create a need to assess liver fat in children.
Histology is considered the most sensitive means of
obtaining pertinent, comprehensive information from the
liver and surpasses imaging and other laboratory data
for several reasons. Liver histology is capable of identi-
fying steatohepatitis and staging liver ﬁbrosis, which
have important prognostic implications. Moreover, his-
tology provides complex and integrated information at a
cellular level, and therefore can reﬁne a diagnosis when
other studies are nonspeciﬁc or suggest multiple
possible diagnoses. In addition, well-preserved histologic
samples serve as an accessible tissue bank for future
investigations. However, the liver biopsy procedure is
invasive and requires sedation with potential risks
including discomfort, bleeding, and infection.
Given the risks of liver biopsy in children, an alternate
means for obtaining diagnostic information and for lon-
gitudinal surveillance of liver fat is desirable, and creates
a niche for imaging liver fat in children. Diagnostic in-
formation about liver abnormalities—including hepatic
steatosis—can be obtained from imaging modalities in a
noninvasive manner and without the need for sedation in
many children. This is particularly relevant for children
with fatty liver, in whom disease monitoring is necessary
for months, years, or even decades. Although there are
many potential advantages, the diagnostic utility of im-
aging for assessment of liver fat in children has not been
evaluated systematically. Although studies in adults have
suggested that imaging may be an accurate means of
assessing hepatic steatosis,2–8 children differ from adults
in several key aspects including body habitus, breath-
holding capacity, and their ability to tolerate imaging
examinations. These factors affect the feasibility, quality,
and technical optimization of imaging examinations and
may affect their diagnostic performance. Hence, valida-
tion in adults does not sufﬁce to establish validity in
children. Independent validation of imaging modalities to
assess liver fat in children is necessary.
To validate an imagingmodality as ameasure of hepatic
steatosis, studies are required in which children are
assessed by both the test modality and a comparison mo-
dality that correctly classiﬁes each subject.Whenassessing
the ability of a test modality to make a quantitative or
semiquantitative measurement of hepatic steatosis, the
study population must use a comparator modality that is
sufﬁciently quantitative and must include a sufﬁcient
representation of children across the spectrum of hepatic
steatosis, including those without hepatic steatosis.
Our aim was to perform a systematic review of the
literature, detailing studies that have evaluated imaging
liver fat in children using ultrasound, computed tomog-
raphy (CT), magnetic resonance imaging (MRI), or mag-
netic resonance spectroscopy (MRS) compared with a
sufﬁciently quantitative comparator. The preferred
reference was liver histology. Because of the limitednumbers of studies with histology, we also included
studies that used the quantitative methods of MRI or
MRS as the reference. Studies using histology as the
reference were considered to be of higher quality for the
purposes of establishing recommendations, than studies
using MRI or MRS as the reference. Our goals were as
follows: (1) to critically review and synthesize the col-
lective literature, (2) to make recommendations
regarding the clinical use of imaging to assess liver fat in
children, and (3) to identify potential gaps that may be
addressed by future research studies.Methods
We followed published guidelines for the conduct and
reporting of systematic reviews.9 We performed a
structured keyword search in PubMed to identify orig-
inal research reports published in print or online in
English in peer-reviewed journals between January 1,
1982, and December 31, 2012, that evaluated the per-
formance of imaging modalities to assess hepatic stea-
tosis compared with a quantitative or semiquantitative
reference standard. The search term “imaging liver fat”
and a review of reference sections of all relevant articles
resulted in 1271 studies. The search then was ﬁltered by
age for studies in children (birth to 18 y), resulting in
182 remaining studies. Eligible studies had to assess an
imaging modality using a comparator that was sufﬁ-
ciently quantitative. A total of 173 studies were excluded
based on various criteria (Figure 1). Nine studies
remained for systematic review (Table 1). Three inde-
pendent physicians extracted data from each study to
minimize errors and reduce potential biases. Consensus
of analyzed data was achieved through a structured re-
view of each article in multiple group meetings. All au-
thors then reviewed and revised the material presented.
Table 1. Characteristics of Pediatric Studies Comparing Steatosis by Imaging With a Quantitative Reference
Modality Study Country N Age range, y Population Comparator Deﬁnition for fatty liver
Evaluation of steatosis
severity
Ultrasonography
Paciﬁco, 2007 Italy 50 5–16 Children with BMI >95th
percentile referred for
evaluation for fatty liver upon
detection of hepatomegaly
and/or increased liver
chemistry
MRI MRI HFF 9% Continuous hepatic fat fraction
Pozzato, 2008 Italy 60 6–14 Obese children with white parents
admitted for obesity
MRI MRI HFF 9% MRI HFF 9%
El-Koofy, 2011 Egypt 70 2–13 Obese children were referred from
the Endocrinology Department
for assessment of hepatic
abnormalities; clinical
hepatomegaly, increased ALT
level, and/or echogenic liver
parenchyma by ultrasound
Histology >5% of hepatocytes with
steatosis
Ordinal histologic steatosis score
Shannon, 2011 Italy 208 3–14 Children with biopsy-proven
NAFLD
Histology >5% of hepatocytes with
steatosis
Ordinal histologic steatosis score
Bohte, 2012 The Netherlands 104 8–18 Obese children admitted to a
tertiary center lifestyle
intervention program based on
BMI >30 kg/m2 along with
obesity-related comorbidity
Spectroscopy >1.8% absolute concentration of
spectroscopic liver fat
Center deﬁned MRS cut-off
points for mild, moderate, and
severe steatosis
MRI
Yokoo, 2009 United States 30 8–18 Recruited from the institutional
hepatology and obesity clinics
Spectroscopy Threshold value of 6.25% for
spectroscopic fat fraction
Continuous spectroscopic fat
fraction
Yokoo, 2011 United States 34 10–18 Referred by hepatologists and
surgeons
Spectroscopy Various MRS thresholds: 0.04,
0.06, 0.08, 0.10
Continuous spectroscopic fat
fraction
Paciﬁco, 2011 Italy 25 7–16 Obese Caucasian children with
suspected NAFLD based on
increased serum ALT level and
diffusely hyperechogenic liver
on US, and hyperinsulinism
Histology >5% of hepatocytes with
steatosis
Ordinal histologic steatosis score
Springer, 2011 Germany 29 11–16 Severely obese adolescents
referred for treatment
Spectroscopy Intrahepatic lipid content >5% Continuous spectroscopic fat
fraction
ALT, alanine aminotransferase; BMI, body mass index; HFF, hepatic fat fraction; US, ultrasonography.
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768 Awai et al Clinical Gastroenterology and Hepatology Vol. 12, No. 5Based on the evidence, recommendations were made
in the assessment of fatty liver as a dichotomous
outcome (screening, diagnosis, exclusion) and as a
continuous measure (grading, monitoring change). We
used the classiﬁcation of the Grading of Recommendation
Assessment, Development, and Evaluation (GRADE)
workgroup.10 The GRADE system, developed by a widely
representative group of international guideline de-
velopers, allows for clear separation between the quality
of evidence and the strength of recommendations. The
strength of recommendations in the GRADE system is
classiﬁed as strong (Grade 1) or weak (Grade 2). The
quality of evidence supporting strong or weak recom-
mendations is designated by 1 of 3 levels: high-quality
(A), moderate-quality (B) or low-quality (C). The desig-
nation of quality is based on the likelihood that further
research will change the conﬁdence of the estimate with
A (unlikely to change the conﬁdence in the estimate of
the effect), B (likely to have an important impact), and C
(very likely to impact or change the estimate).
Technical Discussion
To interpret the results, a brief technical discussion is
provided.
Ultrasound
Ultrasound is widely used for the evaluation of hepatic
steatosis11–13 and is based on high-frequency sound wave
propagation. The ultrasonic appearance of normal liver is
similar to other solid organs. Ordinarily, intrahepatic
structures such as hepatic veins can be delineated by
ultrasonic waves. In hepatic steatosis, the presence of lipid
droplets within hepatocytes disturbs the propagation of
the soundwave, causing scatter and attenuation. Aswaves
scatter, more echoes return to the ultrasound transducer.
This increase in signal (echogenicity) from liver is pro-
cessed to yield a liver that is brighter in qualitative com-
parison with the kidney. Attenuation of the ultrasound
waves causes depth-dependent loss of signal, causing
obscuration of vessels, bile ducts, and blurring of the
diaphragm. Collectively, the changes caused by scattering
and attenuation are used to infer hepatic steatosis, but
available ultrasound-based techniques do not permit a
direct quantiﬁable measurement of liver fat.14
Magnetic Resonance Imaging
Chemical-shift MRI exploits differences in resonance
frequencies of water and lipids to differentiate tissues
containing only water from those containing both water
and lipids. Chemical shift occurs because nuclei in
different chemical environments experience slightly dif-
ferent magnetic ﬁeld strengths. The variation in magnetic
ﬁeld strength results from the intrinsic shielding of
surrounding electrons, which partially counteract theforce of the main magnetic ﬁeld. Hydrogen nuclei in
water compared with hydrogen nuclei in lipids have
fewer surrounding electrons. Hydrogen nuclei in water,
therefore, experience a stronger magnetic ﬁeld, and
rotate at a higher resonance frequency.15 The charac-
teristic resonance frequencies of fat and water and the
detection of the signal of fat-speciﬁc frequency allows for
quantitative measurement of hepatic steatosis.
Several techniques are available for MRI assessment of
steatosis. In the 2-point Dixon (or dual-echo) method,
signal intensities from tissues such as liver are compared
in in-phase (IP) and out-of-phase (OP) images. This re-
quires acquisition of 2 sets of gradient-echo images, and
consideration of the echo-time–dependent signal inter-
ference between fat andwater. In OP echo-time, water and
fat signals cancel and therefore the total signal intensity is
lower. In IP echo-time, water and fat signals augment and
therefore the total signal intensity is higher. Normal liver
has similar signal intensity between the OP and IP images
because there is no fat–water interference. In steatosis,
the liver signal intensity is lower and the liver appears
darker on the OP images because of the fat–water signal
interference. In addition to this qualitative measure, MRI
also can estimate quantitative fat content. MRI fat and
water signal intensities increase proportionately to the
respective number of molecules. For quantitative assess-
ment, an IP and OP signal intensity comparison can be
used to calculate a signal fat fraction,16–18 which is deﬁned
as the portion of the fat signal relative to the total (fat þ
water) liver signal. The ability to decompose the overall
hepatic signal to its water and fat components may give
MRI an advantage over other approaches.19 To achieve the
necessary accuracy and to permit a standardized measure
of liver fat content, MRI assessment must include the
appropriate sequence, proper parameters, and complete
correction for confounding factors such as T1 bias, T2*
decay, multipeak spectral interference effects from pro-
tons in fat, noise bias, and eddy currents.6,7,18,20–23Magnetic Resonance Spectroscopy
MRS is regarded as the most accurate method for
quantiﬁcation of hepatic fat content in user-speciﬁed lo-
cations in the liver and has been used in numerous studies
as the reference comparator by which the accuracy of
other methods, including MRI, is gauged.2,5–7,15,18,24 A
volume of at least 4 cm3 is targeted within the liver, and a
nuclear magnetic resonance spectrum is obtained. The
spectral peaks represent chemical moieties of water and
triglyceride molecules. Hydrogen protons in water have a
dominant frequency in the MR spectrum at 4.7 ppm.
Hydrogen protons in the dominant methylene (CH2)
moiety of triglyceride molecules have a frequency peak at
1.2 ppm,15 whereas hydrogen protons in other triglycer-
ide moieties have additional peaks at other frequencies.
Consequently, triglyceride produces a spectrum of mul-
tiple frequency peaks, vs the single large peak created by
May 2014 Imaging Liver Fat in Children 769water.25,26 The MR signal of hydrogen protons in water
and each triglyceride moiety can be identiﬁed by their
unique frequencies, and their cumulative signal amplitude
can be quantiﬁed.25 From the cumulative signal amplitude
of hydrogen in water vs those in fat, the fat fraction can be
determined.
Results
Studies of Ultrasonography Assessment of
Hepatic SteatosisUltrasound compared with liver histology. There were
2 studies identiﬁed that have compared the evaluation of
hepatic steatosis by liver ultrasonography with liver
histology in children. The ﬁrst study evaluated 70 chil-
dren from a pediatric obesity clinic in Cairo, Egypt.27 Of
these children, 34 were clinically believed to have fatty
liver based on the ﬁndings of hepatomegaly, increased
serum alanine aminotransferase activity, and/or an ul-
trasound that was considered positive for hepatic stea-
tosis. These 34 children underwent a liver biopsy. The
liver ultrasound images were graded using semi-
quantitative criteria for steatosis as follows: none (0),
mild (1), moderate (2), or severe (3). Children were
classiﬁed histologically as having normal liver or fatty
liver; however, more speciﬁc grading of the degree of
hepatic steatosis was not reported. Liver histology
showed that 47% (15 of 32) of children with a positive
liver ultrasound for steatosis had fatty liver. The number
of children who had fatty liver but did not have a liver
biopsy was unknown. Therefore, it was not possible to
estimate the negative predictive value of a normal liver
ultrasound. Because of the small numbers of children
with fatty liver, the accuracy of ultrasound grading of
steatosis could not be assessed accurately.
The second study included only children with biopsy-
proven NAFLD in Rome, Italy.28 The study had a large
sample size (n ¼ 208), but did support an assessment of
the relationship between semiquantitative measure-
ments of steatosis by liver ultrasound vs liver histology.
Steatosis by liver ultrasound was graded as follows: none
(0), mild (1), moderate (2), or severe (3). Steatosis by
liver histology was graded as negative (<5% of hepato-
cytes containing fat vacuoles), mild (5%–33% of hepa-
tocytes), moderate (>33% to 66% of hepatocytes), or
severe (>66% of hepatocytes). The Spearman correla-
tion between ultrasound steatosis score and liver his-
tology was good (0.80). However, the individual
ultrasound score category did not accurately predict the
histologic category. There were 12 children who had a
negative ultrasound; of these, 10 (83%) children had a
liver biopsy showing steatosis. Nearly half (29 of 61) of
the children with mild steatosis by ultrasound had
moderate steatosis by liver histology. For children who
had an ultrasound steatosis score of moderate, there was
a wide distribution of histologic severity spanning mild,moderate, and severe steatosis. The investigators also
combined the ultrasound grades of moderate and severe
together for analyses. Of those children with severe
steatosis by liver histology, all had an ultrasound stea-
tosis score of moderate to severe steatosis.
Ultrasound compared with liver magnetic resonance
imaging. Two studies in children used MRI-determined
hepatic fat fraction as the quantitative comparator
against which ultrasound ﬁndings were evaluated. In the
ﬁrst of these studies, Paciﬁco et al29 evaluated 50 obese
children in Rome, Italy, who were preselected for sus-
pected fatty liver based on ﬁndings of hepatomegaly or
liver chemistry values greater than 1.5 times the upper
limit of normal for age. Steatosis by liver ultrasound was
graded as follows: none (0), mild (1), moderate (2), or
severe (3). MRI was performed using a modiﬁed Dixon
method, and the hepatic signal fat fraction was calculated
from the mean pixel signal intensities. For the purposes
of this study, a child was considered to have fatty liver if
the MRI hepatic signal fat fraction was 9% or higher. Of
the children clinically suspected to have fatty liver, only
40% were determined to have fatty liver by MRI. Of
those children with an ultrasound interpreted as positive
for fatty liver, slightly more than half (56%) were
determined to have fatty liver by MRI. The overall
Pearson correlation between ultrasound steatosis score
and liver MRI-determined hepatic fat fraction was mod-
erate (r ¼ 0.68). There was a low rate of false-negative
results (1 of 16). However, there was limited ability to
accurately grade the severity of steatosis. The majority of
children with mild steatosis by ultrasound (12 of 18) had
a negative MRI for fatty liver. For children who had an
ultrasound steatosis score of moderate, there was a wide
range of MRI-determined hepatic signal fat fractions with
values ranging from 1% to 39%.
In the second study, 60 children were referred to a
tertiary care obesity clinic in Milan, Italy.30 All children
underwent liver ultrasound and MRI. Steatosis by liver
ultrasound was graded as follows: none (0), mild (1),
moderate (2), or severe (3). The MRI protocol, specif-
ically the echo time and ﬂip angle, used in this study
differed from that in the Paciﬁco et al29 study. Despite
the differences in imaging parameters, the same
threshold value (9%) was used to determine fatty liver.
Applying the same MRI-based classiﬁcation threshold
may not be valid for techniques that differ in echo time
and ﬂip angle because changes in these parameters alter
the MRI-estimated fat fraction.20 Of those children with
an ultrasound interpreted as positive for fatty liver,
slightly less than half (48%) were determined to have
fatty liver by MRI. The false-positive rate was highest
among those with an ultrasound steatosis score of
1 (mild), with 72% (13 of 18 participants) having a
negative MRI for fatty liver. If one chose to consider only
a hepatic steatosis score of 2 or 3 as positive, the false-
positive rate would be diminished. However, the cost of
doing so in this data set would have been missing 43%
(6 of 14) of children with fatty liver.
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spectroscopy. One study compared liver ultrasonography
with MR spectroscopy in 104 obese adolescents from
an obesity treatment program in Amsterdam, The
Netherlands.31 Liver ultrasound was performed and
steatosis was scored as follows: none (0), mild (1), mod-
erate (2), or severe (3). MRS was performed using the
point resolved spectroscopy technique with T2 correc-
tion. In this study, adolescents were classiﬁed as having
fatty liver if liver fat fraction by spectroscopy was greater
than 1.8%. Despite this low classiﬁcation threshold value,
there were a substantial number of false-positive ultra-
sound interpretations. Of those adolescents with an ul-
trasound interpreted as positive for fatty liver, 22 of 66
did not have fatty liver by MRS. The investigators also
assessed the semiquantitative determination of steatosis
by ultrasound. The false-positive rate was high; of those
with no steatosis on MRS (n ¼ 56), 25 of 56 had ultra-
sound ﬁndings of mild or moderate steatosis. By com-
parison, the false-negative rate was low; of those with a
normal ultrasound (n ¼ 38), only 7 of 38 had a positive
MRS. However, depending on the deﬁnition used, liver
ultrasound correctly identiﬁed the severity of steatosis in
only 40% to 60% of cases. The investigators concluded
that liver ultrasound could not be used to predict the
presence or severity of hepatic steatosis.Studies of Computed Tomography Assessment
of Hepatic Steatosis
No studies in children compared CT assessment of
hepatic steatosis with a quantitative measure. Because of
the exposure to ionizing radiation and the existence of
other imaging modalities free of ionizing radiation, CT
should not be used for the primary purpose of assessing
hepatic steatosis.Studies of Liver Magnetic Resonance Imaging
Assessment of Hepatic Steatosis
Magnetic resonance imaging compared with liver
histology. One study evaluated 25 obese children in Rome,
Italy, with biopsy-proven NAFLD who underwent MRI
before liver biopsy to explore the accuracy of the MRI-
determined hepatic signal fat fraction.32 The MRI method
used in this study was a modiﬁcation of the 2-point Dixon
method.33 Steatosis by liver histology was graded as fol-
lows: grade 0 (<5%), grade 1 (mild; 5%–33%), grade 2
(moderate; 34%–66%), and grade 3 (severe;66%). MRI-
determined hepatic signal fat fraction was correlated
strongly (r ¼ 0.88) with the histologic grade of steatosis
among children with NAFLD. The small sample size pre-
cluded more speciﬁc determinations of accuracy.
Magnetic resonance imaging compared with liver
magnetic resonance spectroscopy. One study compared
MRI with MRS performed exclusively in pediatric par-
ticipants. Springer et al21 studied 29 obese adolescents inTubingen, Germany. All examinations were performed at
1.5 T. Spectroscopy was performed using the stimulated
echo acquisition mode technique without T2 correction.
MRI was performed using fat-selective imaging. The in-
vestigators compared MRI with MRS for the ability to
detect MRS-determined hepatic fat fraction of greater
than 5%. They also evaluated the correlation of MRI-
determined hepatic signal fat fraction with MRS-
measured fat fraction. Depending on where the region
of interest was selected for MRI, the Spearman correla-
tion coefﬁcient ranged from 0.78 to 0.86. Thus, the
values derived were highly correlated but not equivalent.
In this study sample, MRI had a sensitivity of 95% and a
speciﬁcity of 92% for the detection of an MRS-measured
hepatic fat fraction of greater than 5%.
Two studies compared MRI with MRS and were noted
to include some children. Yokoo et al6 examined 110
participants in California, 30 of whom were children, with
the goal of assessing the accuracy of 4 fat-quantiﬁcation
methods using low-ﬂip-angle multi-echo gradient-
recalled-echo MRI at 1.5 T. In this study, a diagnosis of
fatty liver was based on a spectroscopic fat fraction
threshold value of 6.25%. The MRI fat fraction was
calculated using 4 analysis methods, as follows: (1) dual-
echo, (2) triple-echo, (3) multi-echo, and (4) multi-
interference. The dual-echo analysis method did not
correct for T2*, whereas all other methods corrected for
T2*. The multi-interference method also corrected for
multiple spectral interference effects of fat. Depending on
the threshold set to deﬁne fatty liver and the MRI analytic
method used, the diagnostic sensitivity of MRI ranged
from 0.76 to 1.0, and the diagnostic speciﬁcity ranged
from 0.85 to 1.0. Grading accuracy also was assessed. The
dual-echo method had a systemic error resulting in
underestimation of the fat fraction by 2.9%. The triple-
echo method had a small but signiﬁcant error in both
correlation and estimation of fat fraction. The multi-echo
method had an error in correlation, but not in estimated
fat fraction. The multi-interference method with spectral
modeling had the highest quantiﬁcation accuracy.
In a second study by Yokoo et al,7 a similar method-
ology was applied at a higher ﬁeld strength of 3.0 T. The
investigators evaluated MRI methods using 2, 3, or 6
echoes and each of these was assessed using either
single-frequency or multifrequency fat signal modeling.
There were 34 children of a total sample size of 163
participants from Southern California. In this study, the
classiﬁcation accuracy of the 6 imaging methods for fatty
liver was assessed using a range of potential threshold
spectroscopic fat fraction values from 4% to 10%. The
classiﬁcation accuracy of all imaging methods included in
this study ranged from 83% to 96%.Magnetic Resonance Spectroscopy
No studies compared hepatic steatosis measured by
MRS with steatosis assessed by liver histology in children.
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We performed a systematic review of the published
literature in children assessing hepatic steatosis mea-
sured by noninvasive imaging that made use of a quan-
titative comparator. Nine studies were identiﬁed that
tested the validity of ultrasound or MRI assessment of
liver fat. We analyzed studies for the ability to evaluate
the presence or absence of fatty liver as a dichotomous
trait as well as the ability to grade steatosis as an ordinal
trait. This systematic review provides a framework from
which to evaluate the evidence-based utility of these
modalities for diagnosis and grading of hepatic steatosis
in children.Ultrasound: Evidence-Based Utility
In routine practice, ultrasound commonly is used to
determine the presence of fatty liver. However, a sys-
tematic review showed a positive predictive value of
liver ultrasound for fatty liver in children between 47%
and 62%. Thus, the available evidence showed that ul-
trasound did not meet the standard clinical threshold
required to be used as a diagnostic test. This limitation of
ultrasound to accurately classify whether or not a child
has fatty liver stems in part from an inherent property of
ultrasound; it does not measure fat directly, instead, the
relation between ultrasound-derived images and liver fat
is intrinsically subjective and nonquantitative.
In addition to showing the presence of fatty liver,
ultrasound currently is used by many physicians to
exclude fatty liver. The design of the included studies
limited the ability to evaluate this role for ultrasound.
Only one study included children who had a negative
ultrasound but still had a liver biopsy.28 In that study,
most of the negative ultrasounds turned out to be falsely
negative. However, this was an artifact of the study
design, which only included children with known NAFLD.
Thus, the data are lacking regarding the ability of ultra-
sound to exclude fatty liver in children.
Liver ultrasonography has been used widely to grade
the severity of steatosis, primarily in research studies;
however, the evidence reviewed does not support ultra-
sound as a semiquantitative measure of hepatic steatosis.
In the studies reviewed comparing ultrasound with his-
tology, children with mild steatosis by ultrasound were
found to have moderate steatosis by histology in
approximately 50% of cases. Moreover, when ultrasound
was compared with MRI, the majority of children with
mild steatosis by ultrasound were determined not to have
fatty liver by MRI. The grading category of moderate
steatosis did not fare better. Children with an ultrasound
steatosis grade of moderate had steatosis ranging from
mild to severe on liver biopsy and a liver fat fraction on
MRI that ranged from normal to near-maximal. Thus,
current evidence indicates that liver ultrasound lacks the
accuracy to grade steatosis.Magnetic Resonance Imaging Evidence-Based
Utility
In pediatric clinical research studies, MRI has over-
taken ultrasound as the modality of choice for the
noninvasive measurement of hepatic steatosis. In some
institutions, MRI now is used in standard clinical practice
to measure liver fat fraction. The increasing use of MRI is
owing to its availability and promise as a quantitative
measure of hepatic steatosis. However, the evidence base
is extremely limited. Available data do highlight the
importance of performing MRI correctly to compensate
for confounders that introduce error into both the
accuracy and precision of conventional MRI.5–7,20,34,35
A structured review showed that MRI has the potential
for a diagnostic accuracy for steatosis that is on par
with spectroscopy.5–7 Moreover, initial pediatric data
comparing MRI measured liver fat fraction with hepatic
steatosis assessed by liver histology showed a good
correlation between these measures.32 However, the
available evidence is too small to estimate diagnostic
performance.
Both clinicians and radiologists need to be aware that,
because of the presence of confounding factors such as
T1 relaxation, T2(*) decay, multifrequency interference
effects of protons in fat,6,7,18,20,21 noise bias,22 and eddy
currents,23 conventional MRS and MRI methods may be
inaccurate, nonrobust, and nonreproducible. Advanced
MRS and MRI methods address these confounders to
estimate the proton density fat fraction, a standardized
biomarker of liver fat content that is accurate,5,7,36
reproducible across different scanners37,38 and ﬁeld
strengths,37,38 and robust to routine acquisition param-
eter changes that are common in clinical practice and
may occur in clinical trials. Thus, future studies in chil-
dren should focus on implementation and validation of
these advanced MRI and MRS techniques.Clinical and Research Recommendations
Recommendations for the use of ultrasound and MRI
in clinical care are presented in Table 2. The primary role
of ultrasound is in the evaluation of structural problems
within the liver or gallbladder. In addition, ultrasound is
widely used for screening, diagnosis, and grading of he-
patic steatosis. However, data do not support the use of
ultrasound to make a diagnosis of fatty liver. To deter-
mine the ability of ultrasound to accurately exclude fatty
liver, a study must include children who can be deter-
mined not to have NAFLD. It would not be feasible for a
study to perform liver biopsies as a means to prove the
absence of liver disease, studies of ultrasound to exclude
fatty liver will require a noninvasive test to prove the
absence of hepatic steatosis. The best choice would be
MRI. However, such studies are limited by the lack of a
uniform standard for the MRI liver fat fraction that
accurately classiﬁes children as having or not having
Table 2. Recommendations for Imaging Liver Fat in Clinical Care
Goal Modality
Evidence
GradeSupports Does not support Insufﬁcient for recommendation
Screen for fatty liver Ultrasonography C 2B
MRI C 2C
Diagnose fatty liver Ultrasonography C 1B
MRI C 1C
Exclude fatty liver Ultrasonography C 1C
MRI C 1C
Grade hepatic steatosis Ultrasonography C 1B
MRI C 2C
Monitor hepatic steatosis Ultrasonography C 1B
MRI C 1C
772 Awai et al Clinical Gastroenterology and Hepatology Vol. 12, No. 5fatty liver. Therefore, whether or not ultrasound can be
used to exclude hepatic steatosis is an unanswered
research question. The available data also do not support
the use of ultrasound for grading hepatic steatosis in
clinical care or research. The high misclassiﬁcation rate
for ultrasound grading precludes its use as a tool for
disease monitoring in children at this time and would
introduce substantial error into any studies in which it
was used. In contrast, MRI showed promise as a means of
assessing hepatic steatosis. Unfortunately, the evidence-
based data are insufﬁcient to make recommendations
for the use of MRI to assess liver fat in a clinical context
at this time. In addition, it will be important to consider
and evaluate the relative cost of diagnostic imaging
studies.
Research focused on imaging liver fat in children is
limited. Additional research is needed urgently to assess
ultrasound and MRI in large populations of children us-
ing appropriate normal controls. Future studies using
ultrasound should consider the evaluation of emerging
quantitative ultrasound techniques using liver biopsy as
the reference standard for diagnosis and grading hepatic
steatosis in children. There are also several important
research areas to consider for MRI. First, a major priority
for MRI research is to determine a uniform standard for
MRI-determined liver fat fraction that accurately clas-
siﬁes children as having or not having fatty liver. A
proposed value for a cut-off point ranges from 1.8% to
9%; however, determining whether such a cut-off point
exists, and, if so, where it lies, is a crucial research
question. Second, MRI is both spatial and quantitative
and therefore has the potential to grade the severity of
steatosis and assess steatosis across the entire liver;
however, strategies on how to best analyze and use such
data in a standardized and validated way have yet to be
developed. Third, fatty liver monitoring may be the best
use of MRI. After a liver biopsy is performed for purposes
of diagnosis and staging, the MRI-determined liver fat
fraction could be calibrated individually to the index
biopsy. MRI thereafter could be used as a component
of comprehensive disease monitoring over time. Thisstrategy has not yet been evaluated in children, and thus
provides an area for further research.Conclusions
Fatty liver is a common clinical problem for children
and adolescents. Liver biopsy remains the clinical stan-
dard for diagnosing and grading fatty liver disease in
children. Noninvasive imaging modalities to assess liver
fat in children are needed. The available evidence does
not support the use of ultrasound for diagnosis or
grading of fatty liver in children. Data suggest that MRI
may have better utility but sufﬁcient supportive data are
lacking. Improvement in the imaging technology for the
assessment of liver fat in children and the validation of
such technology should be considered an urgent need for
patient care and research.References
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